Influenza Drug Polymorphs Solubility Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for influenza, including vaccines and antiviral drugs, face challenges such as variable effectiveness due to the high mutation rate of the influenza virus, resistance development, and limitations in preventing all strains, necessitating improved formulations with enhanced properties like increased solubility, stability, and bioavailability.
Innovation Solution
Development of polymorphic forms of Compound (1) or its pharmaceutically acceptable salts, specifically crystalline HCl salts with defined X-ray powder diffraction patterns, which are characterized by specific 2-theta values and used in formulations to inhibit influenza virus replication and treat infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral drugs and vaccines are used to treat influenza, then they provide some therapeutic effect, but their effectiveness is variable due to high mutation rate of the influenza virus
Solution Approach 1:
The patent applies parameter changes by developing multiple polymorphic forms of Compound (1) with different physical and chemical parameters (solubility, stability, bioavailability) to overcome the limitations of existing antiviral drugs. The different polymorphic forms allow optimization of drug properties to maintain effectiveness against mutating virus strains.
Solution Approach 2:
The patent employs composite materials by creating polymorphic forms with specific crystalline structures and solvates (e.g., hydrates, alcohol solvates) of Compound (1). These composite structures enhance the drug's stability and solubility properties, improving its ability to effectively combat various influenza strains despite viral mutations.
2Adaptability or versatility
If antiviral drugs are developed to cover all influenza strains, then broader protection is achieved, but resistance development occurs
Solution Approach 1:
The patent applies segmentation by developing distinct polymorphic forms and solvates of Compound (1) with different properties. This segmentation allows for tailored formulations that can be optimized for specific therapeutic needs and administered through different routes (oral, inhalation, parenteral), providing versatile coverage while maintaining drug efficacy and reducing resistance risk.
Solution Approach 2:
The patent employs dynamics by providing multiple polymorphic forms that can be dynamically selected and administered based on the specific clinical situation, virus strain characteristics, and patient needs. This dynamic approach allows optimization of treatment strategies to maintain effectiveness and prevent resistance development.
3Reliability
If polymorphic forms of Compound (1) are developed with improved solubility and stability, then therapeutic effectiveness is enhanced, but formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically developing polymorphic forms with optimized physical parameters (solubility, stability, melting point) and chemical properties. This allows selection of the most appropriate polymorphic form for each specific application and route of administration, enhancing therapeutic effectiveness while managing formulation complexity through rational design.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1)·1/2Η20, Form F of HCl salt of Compound (1)·3Η20, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.